global incidence of non-hodgkin lymphoma - … · global incidence of non-hodgkin lymphoma...

Global incidence of non-Hodgkin lymphomaNon-Hodgkin lymphoma: both sexes, all ages.Estimated age-standardized incidence rate per 100,000.

The incidence of non-Hodgkin lymphoma (NHL) varies by geographic region. The areas with the highest incidence of NHL are North America, Europe, and Australasia, as well as several countries in Africa and South America. <2.9 <4.1 <5.3 <6.8 <16.6

Source Globocan (2011) Graphs and maps. http://globocan.iarc.fr/ (URL accessed 20.02.12).

NHL 07

Section 2Epidemiologyi. Incidence and mortalityWorldwide: Globally, over one million women are diagnosed with breast cancer every year.1 It is the most frequently diagnosed cancer in women1 and the leading cause of cancer death in women.2 Every year more than 500,000 women die from the disease.2

Incidence and mortality ofsome of the most common

cancers for women worldwide

Source WHO GLOBOCAN 2008

288,654

427,586

273,489

217,302

140,163

458,503 Breast

Colorectum

Lung

Stomach

Liver

Ovary

571,204

515,999

348,571

226,312

224,747

1,384,155

Figure 4 Incidence and mortality of some of the most common cancers worldwide

of all new cancer cases in North America are breast cancer

Across the world over one million women are diagnosed with breast cancer every year

Every year more than 500,000 women die from breast cancer worldwide

Source: WHO GLOBOCAN 2008

27%

of all new cancer cases in South America

are breast cancer

27%

of all new cancer cases in Central America are breast cancer

19%

of all new cancer cases in Africa are breast cancer

25%

of all new cancer cases inAustralia & New Zealand are breast cancer

28%

of all new cancer cases in Asia are breast cancer

19%

of all new cancer cases in Europe are breast cancer

28%

Figure 5 The global impact of breast cancer Europe: In Europe over 400,000 women are diagnosed with breast cancer every year and 120,000 women die from the disease. Breast cancer is the most frequently diagnosed cancer in Europe and the leading cause of cancer death in European women.10 It accounts for 17% of female cancer deaths in this region.10

7/ 12

Section 1 Breast Cancer Section 3 Treatment ReferencesSection 2 Epidemiology Section 4 Avastin® (bevacizumab) and breast cancerContents Overview

North America: Over 200,000 women are diagnosed with breast cancer every year in North America.11 Breast cancer is the second most deadly form of cancer in

North American women after lung; it kills over 45,000 women a year,11 representing almost 15% of female cancer deaths in North America.

Global incidence of chronic lymphocytic leukemiaLeukemia: both sexes, all ages.Estimated age-standardized incidence rate.

The incidence of chronic lymphocytic leukemia (CLL) varies by geographic region. The areas with the highest incidence of CLL are North America, Europe and Australasia.

Source Globocan (2011) Graphs and maps. http://globocan.iarc.fr/ (URL accessed on 20.02.12).

<2.2 <3.8 <5.0 <6.5 <11.9

CLL06

Section 2Epidemiologyi. Incidence & mortalityLung cancer is the most common type of cancer worldwide (accounting for 16.5% of all cancers), and is responsible for the greatest number of cancer deaths worldwide.1

Worldwide • 1.6 million new cases of lung cancer are

diagnosed every year.1

• It is the most common cancer in men, and the third most common cancer in women in both developed and developing countries.8

• Lung cancer is the leading cause of cancer mortality and is responsible for 1.38 million deaths each year.1

• Each day, more than 3,000 people die from lung cancer worldwide, equal to two deaths every minute.2

• Almost half of the diagnosed cases of lung cancer occur in developing countries (49.9%), with the incidence generally being lower in women (globally, 12.1 per 100,000 women compared to 35.5 per 100,000 in men).

Accounts for an average of 11.6% of all cancer deaths in South and Central America

Accounts for an average of 16.3% of all cancer deaths in Eastern, South Eastern, South Central and Western Asia

Accounts for 28.4% of all cancer deaths in North America

Parkin MD et al. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55:74-108Allen J et al. Neoadjuvant Chemotherapy in Stage III NSCLC J Natl Compr Canc Netw. 2008 6 (3):285-93Garcia M, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007

Accounts for an average of 20.3% of all cancer deaths in Europe

20.3%

16.3%

28.4%

1.38 1.6 85%

11.6%

Accounts for an average of 22.4% of all cancer deaths in Australia, New Zealand and Micronesia

Accounts for an average of 9% of cancer deaths in Southern and Northern Africa

9%

22.4%

million new cases of lung cancer every year

million deaths from lung cancer every year

of cases are non-small cell lung cancer

North America Central & South America Europe Asia Africa Australia & New Zealand

Figure 3 Lung cancer incidence by region

Section 1 Lung Cancer Section 3 Treatment ReferencesSection 2 Epidemiology Section 4 Avastin® (bevacizumab) and NSCLCContents Overview

*Developed countries defined as Europe, Japan, Australia, New Zealand and North America. Developing countries defined as Africa, Latin America and the Caribbean, Asia, Micronesia, Polynesia and Melanesia

Europe Lung cancer is the leading cause of cancer related death in Europe, accounting for 18.9% of all cancer deaths in Western Europe and 21.1% of all cancer deaths in Northern Europe.8 Approximately 375,000 cases were attributed to lung cancer in

2000 where it accounts for an average of 20.3% of all cancer deaths.8

The average estimated age-standardised incidence per 100,000 population was 71.8 for men and 21.7 for women, across the European Union (25-member states), in 2006.8

North America and Canada Lung cancer is the most common cause of cancer death in North America, accounting for 28.4% of all cancer deaths, and is the third most common type of new cancer cases (14.5%) in this region. North America has one of the highest lung cancer incidence rates for men and women with approximately 1.75 million new cancer cases and deaths in 2007.8

South and Central America Lung cancer is the most common cause of cancer death in South and Central America (accounting for 12% and 11.6% of all cancer deaths,

respectively).8

9/ 14

Source NHL Cyberfamily (2012) Treatment Options http://www.nhlcyberfamily.org/outcomes.htm#ipi (URL accessed on 20.02.12).

Comparing the 5 year survival rate of patients with follicular lymphoma – a common type of non-Hodgkin lymphoma

The average 5 year survival rate for follicular lymphoma patients with 0-1 risk factors

Follicular Lymphoma International Prognostic Index (FLIPI) risk factors:• age 60+• Ann Arbor stage III/IV• LDH (lactate dehydrogenase) > upper limit of normal• hemoglobin < 12g/dL• ≥ 5 nodal sites of disease

The average 5 year survival rate for follicular lymphoma patients with 2 risk factors

The average 5 year survival rate for follicular lymphoma patients with 3 or more risk factors

Survival Mortality

NHL 09a

International Prognostic Index (IPI) risk factors:• age 60+• Ann Arbor stage III/IV• serum LDH (lactate dehydrogenase) > 1 x reference range• performance status ≥ 2• >1 extranodal site

Source The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993). NEJM 329 (14): 987-994.

Comparing the 5 year survival rate of patients with diffuse large B-cell lymphoma (DLBCL) – a common type of non-Hodgkin lymphoma

The average 5 year survival rate for DLBCL patients with 0-1 risk factors

The average 5 year survival rate for DLBCL patients with 2 risk factors

The average 5 year survival rate for DLBCL patients with 3 risk factors

The average 5 year survival rate for DLBCL patients with 4-5 risk factors

Survival Mortality

NHL 09b

On average one in eight women will develop breast cancer at some time in their lives

This is compared to a risk of 1 in 16 of developing lung cancerand 1 in 71 of developing ovarian cancer

Breast Cancer

Lung Cancer

Ovarian Cancer

Source American Cancer Society

Figure 6 Lifetime risk of common female cancers

Source American Cancer Society. These numbers come from the National Cancer Data Base, and are based on people who were diagnosed with breast cancer in 2001 and 2002. Early stage disease was assumed to include stages 0-IIIA; later or advanced stage disease was assumed to include stages IIIB-IV.

The average five year survival rate for early stage breast cancer is 81%

The average five year survival rate for later or advanced stage breast cancer is 35%

Figure 7 Five year survival rates for breast cancer by stageiii. PrognosisCancer statistics often use an ‘overall 5 year survival rate’ to give a better idea of the longer term outlook for people with a particular cancer. It is almost impossible to predict how long an individual patient might live, but 5 year survival rates can give an approximate range. The 5 year survival rate describes on average the ‘amount’ of people that will be alive 5 years after diagnosis. The average 5 year survival rate for women with early stage breast cancer is 81%.3 However, on average only 35% of women with late or advanced stage breast cancer currently survive for 5 years.3

8/ 12

Section 1 Breast Cancer Section 3 Treatment ReferencesSection 2 Epidemiology Section 4 Avastin® (bevacizumab) and breast cancerContents Overview

ii. Lifetime risk of breast cancer On average one in eight women will develop breast cancer in their lifetime. This is double the risk of developing lung cancer, the second most common cancer in women.12, 13

Section 2Epidemiology

Section 1 Ovarian Cancer Section 3 Treatment ReferencesSection 2 Epidemiology Section 4 Avastin® (bevacizumab) and ovarian cancerContents Overview

i. Incidence & mortalityWorldwide Ovarian cancer is diagnosed in nearly a quarter of a million women each year. It is the eighth most common cancer in women and the seventh leading cause of cancer death among women, responsible for approximately 140,000 deaths each year. These figures confirm that globally, ovarian cancer is the most deadly of the gynaecological cancers.1

Over 220,000 new casesof ovarian cancer every year

140,000 women dieeach year from the disease


Age Standardised Rate ASR3< 4< 5<

Cancer Incidence vs Cancer Mortality

Breast1,384,155458,503

Cervix530,232275,008

Uterus288,38773,854

Ovary224,747140,163


Figure 3 Age standardised mortality rate for ovarian cancer

Figure 4 Annual incidence and mortality rates of female cancers worldwide

Europe In 2008, there were approximately 41,448 deaths from ovarian cancer across Europe, accounting for 5.5% of all female cancer deaths. Europeans have the highest incidence of ovarian cancer and it is the fifth most commonly diagnosed female cancer in Europe.1

North America Ovarian cancer is the eighth most commonly diagnosed cancer in women in North America with 23,895 new cases diagnosed in 2008. It accounts for 3% of female cancer diagnoses but 5.6% of female cancer deaths in North America.1

7/ 13


The overall 5-year survival rate for patients with ovarian cancer is 45%Source: American Cancer Society. Cancer Facts and Figures 2007.Atlanta, American Cancer Society 2007.

The 5-year survival rate for patients with breast cancer is up to 89% Source: American Cancer Society. Breast Cancer Facts and Figures 2009-2010.Atlanta, American Cancer Society, Inc.

Figure 5 5-year survival rate of ovarian cancer vs. breast cancerii. PrognosisCancer statistics often use an ‘overall 5-year survival rate’ to give a better idea of the longer term outlook for people with a particular cancer. Over half of women diagnosed with ovarian cancer will not live beyond five years.6 The overall 5-year survival rate for women with ovarian cancer is 45%. This compares to a 5-year survival rate of up to 89% in women diagnosed with breast cancer.6, 7 The reasons for this poor prognosis are that there is no effective screening for ovarian cancer and symptoms can be ambiguous, leading to a high percentage of cases being diagnosed at an advanced stage when the disease is more difficult to treat.

8/ 13

Section 2Epidemiologyi. Incidence & mortalityWorldwide Colorectal cancer is diagnosed in over 1.2 million people globally each year; it is the second most common cancer in women and the third most common cancer in men. The disease is responsible for approximately

609,000 deaths each year (8% of all cancer deaths),1 making it the fourth leading cause of cancer death after lung, stomach and liver cancers.

Europe Colorectal cancer is the most common cancer in Europe, with approximately 430,000 new cases each

year;1 the highest incidence rate of colorectal cancer in the world. It is also the second greatest cause of cancer death in Europe following lung cancer, accounting for 12% of all cancer deaths.

North America There were approximately 177,000 new cases of colorectal cancer

in North America in 2008, making it the second most commonly diagnosed cancer in the region. Colorectal cancer accounted for 11% of all cancer incidence and 9% of all cancer deaths in North America in the same year.1

7/ 13

Section 1 Colorectal cancer Section 3 Treatment ReferencesSection 2 Epidemiology Section 4 Avastin® (bevacizumab) and colorectal cancerContents Overview

1.2 million new cases each year

4th leading cause of cancer death globally

5.3% of all cancer deaths in Africa

12.8% of all cancer deaths in Australia & New Zealand

12.8% of all cancer deaths in Australia & New Zealand

Responsible for 8% of all cancer deaths

Source WHO IARC GLOBOCAN, Cancer incidence and Mortality Worldwide in 2008 at http://globocan.iarc.fr/

Figure 3 Colorectal deaths by region, as a percentage of the incidence of all cancers Figure 4 Incidence and mortality of some of the most common cancers worldwide

Source WHO IARC GLOBOCAN, Cancer incidence and Mortality Worldwide in 2008 at http://globocan.iarc.fr/

Stomach640,031

463,930348,571

273,489

Colorectal663,904

320,397571,204

288,654

Liver523,432

478,134226,312217,592

Lung1,092,056

948,993515,999

427,586Incidence and mortality of

some of the most commoncancers worldwide

Male incidenceMale mortality

Female incidencemortality

899,102258,133

1,384,155458,503

Prostate

Breast

Average 5 year survival rates at Stage I NSCLC: 58%

Cancer Research UK: http://www.cancerhelp.org.uk/type/lung-cancer/treatment/statistics-and-outlook-for-lung-cancer#nonsmall

Average 5 year survival rates at Stage IV NSCLC: 7.5%

PrognosisCancer statistics often use an ‘overall 5-year survival rate’ to give a better idea of the longer term outlook for people with a particular cancer. Five year survival rates for lung cancer are poor when compared to other high incidence cancers. For example, the five year survival rate for patients with breast cancer is up to 89%.3 For lung cancer patients that figure is only around 15%.4

Section 1 Lung Cancer Section 3 Treatment ReferencesSection 2 Epidemiology Section 4 Avastin® (bevacizumab) and NSCLCContents Overview

Figure 2 Lung cancer average 5 year survival rates depending on stage at diagnosis

8/ 14

8/ 13

Section 1 Colorectal cancer Section 3 Treatment ReferencesSection 2 Epidemiology Section 4 Avastin® (bevacizumab) and colorectal cancerContents Overview

Source Altekruse SF et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/

5-year survival rates for early-stage CRC: up to 90%

5-year survival rates forlater-stage CRC: 12%

Colorectal cancer average 5-year survival rate depending on stage of diagnosis

Survivors Fatalities

Figure 5 Incidence and mortality of some of the most common cancers worldwideii. PrognosisCancer statistics often use an ‘overall 5-year survival rate’ to give a better idea of the longer term outlook for people with a particular cancer. The overall 5-year survival rate for colorectal cancer patients is 65%,17 although this differs greatly depending on how advanced the cancer is.

The 5-year survival rate for a patient diagnosed with stage I or II colorectal cancer, where the tumour is localised to the colon, is up to 90%. Approximately two fifths of patients are diagnosed at this stage. However the 5-year survival rate for patients diagnosed with stage IV disease, once the cancer has metastasised to other organs, is only 12%.17


The overall 5-year survival rate for patients with ovarian cancer is 45%Source: American Cancer Society. Cancer Facts and Figures 2007.Atlanta, American Cancer Society 2007.

The 5-year survival rate for patients with breast cancer is up to 89% Source: American Cancer Society. Breast Cancer Facts and Figures 2009-2010.Atlanta, American Cancer Society, Inc.

Figure 5 5-year survival rate of ovarian cancer vs. breast cancerii. PrognosisCancer statistics often use an ‘overall 5-year survival rate’ to give a better idea of the longer term outlook for people with a particular cancer. Over half of women diagnosed with ovarian cancer will not live beyond five years.6 The overall 5-year survival rate for women with ovarian cancer is 45%. This compares to a 5-year survival rate of up to 89% in women diagnosed with breast cancer.6, 7 The reasons for this poor prognosis are that there is no effective screening for ovarian cancer and symptoms can be ambiguous, leading to a high percentage of cases being diagnosed at an advanced stage when the disease is more difficult to treat.

8/ 13

global incidence of non-hodgkin lymphoma - … · global incidence of non-hodgkin lymphoma...

Documents